AIDS TREATMENT NEWS Issue #384, October 18, 2002
John S. James
On October 11 Roche and Trimeris, Inc. announced that the FDA had granted priority review to FUZEON (TM) (generic name enfuvirtide, formerly known as T-20). This means that the FDA plans to review the application for approval in six months, and announce the results by March 16, 2003 (six months after the application for approval was submitted).
Enfuvirtide works differently from any currently approved HIV drugs: it blocks a step in the process by which HIV fuses with a cell membrane and enters the cell. Since it has an entirely different mechanism of action, virus that has become resistant to approved drugs will not automatically be resistant to this one. However, resistance to enfuvirtide does develop, as with other antiretrovirals. This drug also must only be used in combination treatments, never alone.
Enfuvirtide must be injected twice a day, can be difficult to use, and is difficult to manufacture so it will probably be expensive. For these reasons it will likely be used mainly by patients who do not have other good options.
021018
ATN38402
Copyright © 2002 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .